Comparative Pharmacology
Head-to-head clinical analysis: LAMIVUDINE STAVUDINE versus LAMIVUDINE ZIDOVUDINE TABS 150MG 300MG CO PACKAGED WITH NEVIRAPINE TABS 200MG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMIVUDINE STAVUDINE versus LAMIVUDINE ZIDOVUDINE TABS 150MG 300MG CO PACKAGED WITH NEVIRAPINE TABS 200MG.
LAMIVUDINE; STAVUDINE vs LAMIVUDINE, ZIDOVUDINE TABS 150MG/300MG CO-PACKAGED WITH NEVIRAPINE TABS 200MG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase via DNA chain termination after intracellular phosphorylation to lamivudine triphosphate. Stavudine is also an NRTI that inhibits HIV-1 reverse transcriptase after phosphorylation to stavudine triphosphate.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase via DNA chain termination after intracellular phosphorylation to lamivudine triphosphate. Zidovudine is also an NRTI that inhibits HIV reverse transcriptase after phosphorylation to zidovudine triphosphate. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing enzyme inhibition.
Lamivudine 150 mg plus stavudine 30 mg orally twice daily. For patients weighing ≥60 kg, stavudine 40 mg twice daily.
One tablet of lamivudine/zidovudine (150 mg/300 mg) orally twice daily. One tablet of nevirapine (200 mg) orally once daily for 14 days, then one tablet twice daily thereafter.
None Documented
None Documented
Lamivudine: 5-7 hours in adults; prolonged to 19-28 hours in severe renal impairment (CrCl <10 mL/min). Stavudine: 1.0-1.6 hours; prolonged to 7.4-8.2 hours in severe renal impairment.
Lamivudine: 5-7 hours (terminal half-life); prolonged to ~10-15 hours in advanced HIV infection; increased with renal impairment. Zidovudine: 0.5-3 hours (mean ~1 hour); prolonged to ~1.5-3 hours in renal impairment; intracellular active metabolite zidovudine-triphosphate has half-life ~3-7 hours. Nevirapine: ~25-30 hours (single dose), ~40-60 hours with multiple dosing (autoinduction reduces to ~20-30 hours after 2-4 weeks).
Lamivudine: 70% renal excretion via glomerular filtration and active tubular secretion as unchanged drug; 5-10% fecal. Stavudine: 40% renal excretion via glomerular filtration and active tubular secretion; 34-39% unchanged in urine; fecal excretion minimal.
Lamivudine: ~70% renal (glomerular filtration and active tubular secretion) as unchanged drug; ~30% metabolized to inactive metabolites (trans-sulfoxide) excreted renally. Zidovudine: ~75% renal (metabolite zidovudine-glucuronide) and ~20% unchanged; ~5% fecal. Nevirapine: ~80% renal (metabolites, mainly 2-hydroxy- and 3-hydroxy-nevirapine glucuronides), ~10% fecal, <5% unchanged.
Category A/B
Category A/B
NRTI
NRTI